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ScotlandReceived Nov 19, 2020, and in revised form Dec 2, 2020. Accepted for publication Dec 4, 2020.Purpose: Current treatments for coronavirus disease 2019 (COVID-19) lung disease have limited efficacy. Low-dose radiation
therapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we
explored clinicians’ perspectives to identify barriers to testing LDRT in clinical trials and implementing it in clinical practice.
Methods and Materials: Semistructured interviews were undertaken with 6 clinicians from 3 medical disciplines. Interviews
were recorded, transcribed verbatim, and analyzed thematically, using a framework approach. Common themes regarding bar-
riers to using LDRT for COVID-19 lung disease were identified from the data.
Results: Three categories of barriers emerged: (1) the potential to do harm to the patient, including difficulty in predicting harm
and lack of existing data to inform quantification of risks; (2) the feasibility of trialing this novel treatment strategy in the clinical
setting, in particular trial design and recruitment, patient selection and buy-in from relevant clinician groups; and (3) the logistics
of delivering the treatment, in particular risks of transmission to other patients and resources required for patient transfer.
Conclusions: This study identified several barriers thatmay impede the evaluation and subsequent implementation of LDRTas a
treatment for COVID-19 lung disease, from the perspectives of clinicians in 3 relevant specialties. By documenting and articu-
lating these concerns, we hope to enhance discussion of why these barriers exist, and enable them to be addressed in a proactive
manner to facilitate research into the potential benefits of radiation treatment for patients with COVID-19 lung disease going
forward.  2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Corresponding author: Catherine R. Hanna, FRCR; E-mail: catherine.
hanna@glasgow.ac.uk
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The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is having an unprecedented health and so-
cietal impact, with more than 54 million cases and 1.3
million deaths reported globally.1 Patients with SARS-
CoV-2 who develop severe pneumonia and acute respira-
tory distress syndrome have the highest mortality rates.2
The lung pathology is characterized by diffuse alveolar
damage suggestive of acute respiratory distress syndrome
with alveolar infiltration by immune cells and proin-
flammatory cytokines.3-5 Research efforts to find effective
treatments have included evaluation of low-dose radiation
therapy (LDRT) with the rationale that LDRT has anti-
inflammatory and immune-modulatory effects, which may
counteract the pro-inflammatory state observed in SARS-
CoV2einfected patients.5,6
Initiation of clinical trials to test LDRT has been slow,
with preliminary results from 2 studies treating a total of 10
patients reported to date.7,8 Individuals and groups within
the radiation oncology community have expressed concerns
about the acceptability and validity of using radiation
therapy in this context.9,10 Better understanding of clini-
cians’ concerns regarding the use of LDRT for coronavirus
disease 2019 (COVID-19) lung disease would enable these
issues to be addressed proactively, facilitating high-quality
research in this field. In this study we aimed to identify and
characterize these concerns by investigating multidisci-
plinary clinician perspectives on the topic.Methods
Semistructured interviews were undertaken by one
researcher in July and August 2020. Potential participants
were consultant-level medical professionals working in
the UK National Health Service within the disciplines of
radiation oncology, intensive care, or respiratory medi-
cine. These specialties were chosen to represent clinicians
involved in treating patients with COVID-19 lung disease
and/or responsible for delivering radiation treatment. A
convenience sample, identified by members of the
research team, was initially approached. Initially, there
were 2 replies out of 6 individuals approached. A snow-
balling technique, whereby clinicians who participated or
declined were asked to identify alternative participants,
was used. In this way, an additional 7 clinicians were
approached and 4 of these agreed to participate. In total,
13 clinicians were invited and 6 agreed to be interviewed
(3 men, 3 women) with representation from all 3 medical
disciplines (2 of each). This study received ethical
approval from the University of Glasgow Medical, Vet-
erinary, and Life Sciences Ethics Committee (project
number: 200190165) and was approved by the Greater
Glasgow and Clyde Research and Innovation Department
(ref: GN20HS293).The interviews were recorded using video conferencing,
and the audio recordings transcribed verbatim. Thematic
analysis11 using a framework approach12 was undertaken
by 2 researchers (CRH, KAR) who each coded all of the
interviews. Codes and themes were developed deductively
and iteratively refined after coding each interview via
comparison of coding outcomes and discussion of dis-
crepancies. Microsoft Excel 2016 was used for all analyses.
Results
Three broad categories of barriers to using and testing
LDRT for COVID-19 emerged from the interviews (Fig. E1
in Appendix E1): (1) potential to do harm; (2) feasibility of
clinically trialing this novel treatment strategy (“trial-
ability”); and (3) logistics of treatment delivery. The key
opinions from each participant are summarized in Table 1,
and direct quotations that align with the themes identified
are provided in Appendix E2 (Table E1)
Harms
There was concern that LDRT could make an inflammatory
state worse and that predicting the likelihood of this harm
would be difficult. Radiation oncology participants in
particular were concerned that it would not be possible to test
patients’ lung function accurately, which is normal practice
before prescribing radiation therapy for lung cancer. Some
interviewees were reassured by the low radiation dose being
used; others thought that the risk of exacerbating an in-
flammatory state was likely to be idiosyncratic and not dose
dependent. Opinions were mixed regarding whether the
lungs were the optimal target. One intensive care unit and
one respiratory consultant agreed with treating the lungs
whereas one of the radiation oncologists favored targeting
lymphoid organs. There was a consistent opinion that
assessing the risks and benefits was especially difficult
because of the novelty of the treatment and the apparent lack
of supporting data. It was highlighted that previous reports of
using LDRT to treat pneumonia, both contemporary and
historical, did not fully allay concerns about potential harms.
Trialability
Participants discussed the challenge of designing a clinical
trial with meaningful endpoints to measure treatment
benefit, and of obtaining an adequate sample size. The
primary endpoints suggested by these participants included
mortality, specifically in line with the RECOVERY trial
endpoint, as well as an endpoint that would measure a
reduction in oxygen requirement. Several clinicians were of
the opinion that the benefit would need to be large for 2
reasons: to be able to detect a benefit within a clinical trial
(especially if patient numbers were small), and to support a
change in practice. Participants were aware of preliminary
Table 1 Clinician attitudes on using LDRT for COVID-19 lung disease
Radiation oncology 1 Radiation oncology 2 Respiratory 1 Respiratory 2 ICU 1 ICU 2
Harms
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Abbreviations: COVID-19 Z coronavirus disease 2019; CPAP Z continuous positive airway pressure; HDU Z high dependency unit; ICU Z intensive care unit; LDRT Z low-dose radiation therapy;
PE Z pulmonary embolism.
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number of patients. Nevertheless, they noted that early-
phase trials may not be large enough to provide reassurance
regarding potential harms, and that proving efficacy of
LDRT compared with standard care would be difficult
because a proportion of patients would recover spontane-
ously. Difficulties in predicting future prevalence of
COVID-19 and how this might affect recruitment to a
clinical trial testing LDRT were also highlighted. Despite
this, there was general agreement that it was easier to
initiate and recruit to COVID-19 trials compared with trials
in other disease types.
Second, the challenge of ensuring “buy-in” from clinicians
was noted, especially given the novelty of the intervention
and the perceived comparison to drug treatments being tested
in competing trials. It was highlighted that the medical pro-
fessional recruiting patients would likely be a respiratory
physician and/or intensivist who is not familiar with radiation
therapy, whereas the clinician delivering the treatment would
be a radiation oncologist. This was considered unusual for a
clinical trial and posed challenges regarding multidisciplinary
working, communication, and trust.
Finally, the challenge of understanding which patients
would or would not be optimal candidates for a trial was
identified. No specific age cutoff was identified, and
although obesity and ethnicity were mentioned as important
patient-related risk factors, there was no consensus that
these would be sufficient for patient selection. One of the
respiratory physicians was aware of preliminary data from
the RESCUE 1-19 trial, which recruited mainly older pa-
tients and expressed reassurance that including older pa-
tients in future trials would be acceptable.
There was agreement about excluding patients with
underlying lung disease, additional reasons for hypoxemia
such as pulmonary embolism, or requiring intensive care
level medical support. These were all identified as factors
that would increase the likelihood of harm as well as dif-
ficulties delivering treatment. Considering this dilemma,
some clinicians suggested that optimal candidates might be
those requiring level 2 hospital care, with a moderate ox-
ygen requirement on approximately day 10 of the disease
trajectory.Logistics
The final barriers that emergedwere logistical. Amajor focus
was the transfer of patients frommedical wards to a radiation
therapy department and, aside from the potential harm
caused, the practicalities of performing that transfer within
current resource levels. Participant comments related to the
lack of higher level (intensive care unit) support on radiation
therapy sites and the risk of transmission to other patients in
the radiation therapy department. Lastly, the ability to
implement LDRT in a real-world setting in terms of re-
sources, cost, and scalability was seen as a barrier, even if it
were shown to be effective in clinical trials.Discussion
This is the first study to capture clinician attitudes regarding
the use of LDRT for COVID-19 lung disease. Our findings
have implications for researchers evaluating the role of
LDRT in COVID-19 lung disease and physicians consid-
ering its implementation in clinical practice.
Specifically, there was apprehension about aggravating
pulmonary inflammation and a lack of evidence to inform
the likelihood of this occurring. Emerging safety data from
ongoing early-phase trials and appropriate patient selection,
informed by knowledge of previous lung pathology and/or
radiologic evaluation of baseline lung damage, will help to
address this concern. Increasing understanding of the
COVID-19 disease trajectory and data from control arms of
ongoing randomized trials will also support identification
of meaningful endpoints for larger-scale clinical trials. The
concern regarding the distinction between the recruiting
versus treating clinician raises an important point about the
uniqueness of using radiation treatment for a nonmalignant
condition and indicates that robust interdisciplinary re-
lationships will be required for successful setup and
running of a LDRT/COVID-19 trial. Finally, logistical
concerns would need to be proactively addressed. The risk
of transmission is not unique to radiation therapy, but there
are specific challenges associated with vulnerable cancer
patients receiving treatment in the same departments. Also,
radiation therapy infrastructure is well developed in many
countries but not always colocated with acute or intensive
care facilities and capacity to treat additional, noncancer
patients may be limited.
Participants in this study suggested that appropriate
primary endpoints for a trial to investigate LDRT for
COVID-19 lung disease would be mortality or a reduction
in oxygen requirement. Future research is required to
investigate what magnitude of benefit would need to be
demonstrated in a clinical trial to support implementation
of LDRT in a real-world setting. Our study participants
made clear that any trial conducted to investigate LDRT
may compete with trials assessing drug treatments, and that
patients receiving LDRT in the context of a clinical trial
would very likely already be receiving steroids, given the
results of the RECOVERY trial.13 It would be particularly
interesting to investigate how clinicians envisage LDRT
would be used alongside other potential therapies such as
steroids and antivirals, and if the benefit from LDRT would
need to be at least equivalent to benefits seen for other
novel therapies to be used in practice.
Our study has limitations. First, study participants were
all from one location and it is unclear if the same barriers
exist globally. If they do, it would be informative to un-
derstand how they were addressed and overcome in those
centers in which trials have opened.14 This raises a broader
question about variation in risk attitudes in the context of
novel therapies between health care systems or geographic
regions. We were not surprised that results from current
trials were not commonly discussed, considering the
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at the time the interviews were conducted.
Second, only 2 clinicians were interviewed from each
discipline. The notion of sample size and data saturation
within qualitative research remains much debated.15 The
study was not intended to be a comprehensive investigation
of all possible attitudes to LDRT for COVID-19 lung dis-
ease, but rather a pragmatic, yet informative and timely
approach to explore common themes from interviewing a
purposive sample of clinicians. Lastly, we did not seek the
patient perspective on using LDRT for COVID-19 lung
disease but appreciate this to be an important, comple-
mentary avenue of research.
In conclusion, we recognized the difficulty of setting up a
multidisciplinary study investigating a novel therapy within
the field of radiation oncology and have demonstrated the
value of conducting a qualitative study to determine the
feasibility and acceptability of this research. Specifically, we
have identified the main barriers to the use of LDRT for
COVID-19. Open discussion of these barriers will facilitate
high-quality research in this field. Future research could
build on the results from this study by using a more quan-
titative approach to investigate the magnitude of benefit that
would be required from a clinical trial investigating LDRT
for COVID-19 to change clinical practice.
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